tyrosine has been researched along with dalteparin in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 31 (79.49) | 29.6817 |
| 2010's | 6 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Despotis, GJ; Moon, MR; Skubas, NJ; Vlasnic, JJ | 1 |
| Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD | 1 |
| White, HD | 1 |
| Collard, CD; Lewis, W | 1 |
| Morais, J | 1 |
| Braunwald, E; Califf, RM; Cannon, CP; Fox, KA; Fuster, V; Gibler, WB; Harrington, RA; King, SB; Kleiman, NS; Theroux, P; Topol, EJ; Van de Werf, F; White, HD; Willerson, JT | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Fox, KA; Gensini, GF; Gurfinkel, EP; Huber, K; Le-Louer, V; Maritz, F; Timerman, A; Vittori, L; White, H | 1 |
| Cohen, M | 2 |
| Ferguson, JJ | 1 |
| Ahmad, S; Fareed, J; Jeske, WP; Ma, Q; Walenga, JM | 1 |
| Goldmann, BU; Hamm, CW | 1 |
| Vernon, SM | 1 |
| Bilheimer, D; Blazing, MA; Braunwald, E; Califf, RM; De Lemos, JA; Dyke, CK | 1 |
| Breddin, HK; Esslinger, HU; Graff, J; Harder, S; Kirchmaier, CM; Klinkhardt, U; Westrup, D | 1 |
| Banaszewski, M; Konopka, A; Stepinska, J; Szajewski, T | 1 |
| Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD | 1 |
| Ackman, M; Humphries, K; Jackevicius, C; Kertland, H; Shalansky, SJ; Tsuyuki, R; Virk, R | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD | 1 |
| Herrmann, HC | 1 |
| Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
| Cohen, M; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L | 1 |
| Aydin, M; Bilge, M; Gursurer, M; Ozdemir, H; Ozeren, A; Savranlar, A | 1 |
| Cam, N; Okmen, E; Ozen, E; Sanli, A; Tartan, Z; Uyarel, H | 1 |
| Adgey, AA; Manoharan, G | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; Giugliano, RP; Harrington, RA; Morrow, DA; Murphy, SA; Roe, MT; Sabatine, MS | 1 |
| Day, JR; Haskard, DO; Landis, RC; Malik, IS; Nadra, I; Poullis, M; Taylor, KM; Weerasinghe, A | 1 |
| Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD | 1 |
| Bilheimer, DW; Blazing, MA; Brady, WE; Braunwald, E; Califf, RM; de Lemos, JA; Fox, KA; Lewis, EF; Palmisano, J; Pfeffer, M; Ramsey, KE; White, HD; Wiviott, SD | 1 |
| Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH | 1 |
| Cohen, EA; Fort, S; Godin-Edgecombe, M; Madan, M; Naqvi, SZ; Paradiso-Hardy, FL; Phillips, AM; Radhakrishnan, S; Reis, M; Shanmugasegaram, S; Sparling, C | 1 |
| Barutcu, I; Boztosun, B; Gunes, Y; Kirma, C | 1 |
| Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH | 1 |
| Aroney, CN; Bett, JH; Perrin, EJ; Ray, MJ; Walters, DL; Wood, P | 1 |
| Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J | 1 |
| Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN | 1 |
| Sachithanandan, A | 1 |
| Ge, YG; Li, WM; Ni, ZH; Wang, HS; Wang, LF; Xu, L; Yang, XC; Zhang, DP | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
7 review(s) available for tyrosine and dalteparin
| Article | Year |
|---|---|
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
Topics: Acetates; Angina, Unstable; Anticoagulants; Confidence Intervals; Controlled Clinical Trials as Topic; Enoxaparin; Female; Humans; Male; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Survival Rate; Treatment Outcome; Tyrosine | 2000 |
Prognostic value of cardiac troponins in patients with acute coronary disease.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Dalteparin; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Male; Multicenter Studies as Topic; Myocardial Infarction; Prognosis; Prospective Studies; Tirofiban; Troponin I; Tyrosine | 2000 |
Redefining medical treatment in the management of unstable angina.
Topics: Abciximab; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Diagnosis, Differential; Enoxaparin; Eptifibatide; Government Agencies; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; National Institutes of Health (U.S.); Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Risk; Time Factors; Tirofiban; Troponin I; Troponin T; Tyrosine; United States | 2000 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Nadroparin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Transaminases; Tyrosine | 2001 |
Defining optimal therapy for the thrombolysis-ineligible patient.
Topics: Acute Disease; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Risk Assessment; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
19 trial(s) available for tyrosine and dalteparin
| Article | Year |
|---|---|
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Topics: Adult; Aged; Clinical Protocols; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Survival Rate; Tirofiban; Tyrosine | 2000 |
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Feasibility Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; North America; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Simvastatin; Tirofiban; Tyrosine | 2001 |
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Topics: Abciximab; Adolescent; Adult; Antibodies, Monoclonal; Anticoagulants; Binding, Competitive; Bleeding Time; Blood Platelets; Drug Interactions; Factor Xa Inhibitors; Fibrinogen; Flow Cytometry; Heparin; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Partial Thromboplastin Time; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Selectins; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Tyrosine | 2003 |
Optimizing outcomes in ST-segment elevation myocardial infarction.
Topics: Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
Topics: Age Factors; Aged; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
Topics: Aged; Angina, Unstable; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Therapy, Combination; Elective Surgical Procedures; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Humans; Integrin alpha2; Integrin beta3; Male; Membrane Glycoproteins; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Biomarkers; Blood Coagulation Factors; Blood Platelets; CD40 Ligand; Enoxaparin; Female; Flow Cytometry; Heparin; Humans; Inflammation; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Tirofiban; Tyrosine | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Female; Follow-Up Studies; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Reference Values; Severity of Illness Index; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Dalteparin; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
13 other study(ies) available for tyrosine and dalteparin
| Article | Year |
|---|---|
Preoperative use of enoxaparin and tirofiban: possible association with increased bleeding postbypass.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Coronary Artery Bypass; Enoxaparin; Humans; Male; Postoperative Hemorrhage; Tirofiban; Tyrosine | 1999 |
Does perioperative antithrombotic therapy increase the likelihood of a postoperative coagulopathy after cardiac surgery?
Topics: Cardiac Surgical Procedures; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Humans; Intraoperative Period; Postoperative Hemorrhage; Tirofiban; Tyrosine | 2000 |
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Topics: Blood Platelets; Dose-Response Relationship, Drug; Drug Interactions; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thromboplastin; Tirofiban; Tyrosine | 2001 |
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Retrospective Studies; Risk Factors; Syndrome; Terminology as Topic; Tirofiban; Troponin I; Troponin T; Tyrosine | 2001 |
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Tirofiban; Tyrosine; Vascular Patency | 2002 |
Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
Topics: Abciximab; Antibodies, Monoclonal; Canada; Cardiovascular Agents; Clopidogrel; Dalteparin; Data Collection; Drug Utilization; Enoxaparin; Eptifibatide; Formularies, Hospital as Topic; Health Services Accessibility; Hematologic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Pharmacy and Therapeutics Committee; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome.
Topics: Acute Disease; Aged; Anticoagulants; Coronary Disease; Enoxaparin; Hematoma; Humans; Male; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Retroperitoneal Space; Tirofiban; Tyrosine | 2003 |
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials, Phase II as Topic; Cohort Studies; Coronary Angiography; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Tenecteplase; Thrombolytic Therapy; Time Factors; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2004 |
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Restenosis; Enoxaparin; Eptifibatide; Flow Cytometry; Hemostatics; Heparin; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Thrombin; Tirofiban; Tyrosine | 2004 |
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Female; Humans; Infusion Pumps; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Failure; Treatment Outcome; Tyrosine; Warfarin | 2006 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Right | 2008 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, Induced; Heparin; Humans; Infant, Newborn; Live Birth; Male; Polysaccharides; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Trimester, Second; Pulmonary Embolism; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine; Venous Thrombosis; Warfarin | 2010 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, Induced; Heparin; Humans; Polysaccharides; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Trimester, Second; Pulmonary Embolism; Risk Assessment; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine; Ultrasonography; Venous Thrombosis; Warfarin | 2010 |